Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.

Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.

Item
http://www.wikidata.org/entity/Q37123981
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gainPharmacological manipulations in animal models of anorexia and binge eating in relation to humans.The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.Hyaluronic acid-based hydrogel enhances neuronal survival in spinal cord slice cultures from postnatal mice.Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.Modelling olanzapine-induced weight gain in rats.The rapid hydrolysis of chlordiazepoxide to demoxepam may affect the outcome of chronic osmotic minipump studies.Olanzapine induced biochemical and histopathological changes after its chronic administration in rats.Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.The effect of ranitidine on olanzapine-induced weight gain.Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats.Behavioral, clinical and pathological effects of multiple daily intraperitoneal injections on female mice.Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.
P2860

Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.

Item
http://www.wikidata.org/entity/Q37123981
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@en
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@nl
type
label
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@en
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@nl
prefLabel
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@en
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Olanzapine-induced weight gain ...... ion of olanzapine in solution.
@en
P2093
P304
P31
P356
10.1016/J.EJPHAR.2007.11.078
P407
P433
P478
P577
P5875
P698
P921